# Eribulin Treatment as 1st-line or 2nd-line Chemotherapy for HER2-negative Hormone-resistant Inoperable or Recurrent Metastatic Breast Cancer

> **NCT02551263** · — · COMPLETED · sponsor: **Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan** · enrollment: 201 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Eribulin

## Key facts

- **NCT ID:** NCT02551263
- **Lead sponsor:** Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07-22
- **Primary completion:** 2020-07
- **Final completion:** 2020-07
- **Target enrollment:** 201 (ACTUAL)
- **Last updated:** 2021-06-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02551263

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02551263, "Eribulin Treatment as 1st-line or 2nd-line Chemotherapy for HER2-negative Hormone-resistant Inoperable or Recurrent Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02551263. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*